Newsroom

At the time of this announcement, the UK review website BestReviews.Guide had tested blood ketone monitors on the market and selected its ten best monitors worldwide. eBketone took first place; together with its derivative versions, it occupied all three top positions.

At the time of this announcement, eBuricacid and its derivative versions had been ranked third and fifth among the world’s best uric acid monitors by the US consumer review website Don’t Waste Your Money.

CORESENCE participated in the 2022 Asia Beauty, Skincare and Biotechnology Health Expo.

CORESENCE participated in the 2022 Taipei Spring International Beauty Expo.

CORESENCE participated in the Taipei Spring International Beauty Expo, strengthening relationships and establishing new business contacts with exhibitors and visitors. It also presented cosmetics and skincare products, innovative packaging solutions, and insights into market trends.

The Commercial Times special report on epidemic prevention featured the article “Visgeneer’s blue-ocean strategy delivers results, taking operations to the next level.”

The Commercial Times, page C4, “Affluent Living / Industry and Economy,” featured the article “Visgeneer’s blue-ocean strategy delivers results: light at the end of the tunnel.”

CORESENCE participated in the Taipei Beauty Expo, strengthening relationships and establishing new business contacts with exhibitors and visitors. It also presented cosmetics and skincare products, innovative packaging solutions, and insights into market trends.

The Commercial Times, page A18, “Smart Healthcare,” featured the article “Visgeneer subsidiary completes new factory, with promising prospects.”

The Commercial Times “Smart Industries” section featured the article “Visgeneer’s tea tree products support public health.”

The Commercial Times, page C1, “Industry and Economy Focus,” featured the article “Visgeneer targets new blue-ocean markets and builds new technologies.”

The Commercial Times “Biotechnology Highlights” section featured the article “Visgeneer develops new technologies and positions itself in blue-ocean markets.”

Visgeneer participated in MEDICA 2019 in Düsseldorf, Germany, presenting its newly developed blood ketone and uric acid monitoring systems to an international audience. The announcement described the systems as compact, accurate and fast, and as requiring the world’s lowest blood sample volume, and reported recognition and praise from attendees.

Congratulations to CORESENCE on receiving a Gold Award at the 2019 Monde Selection quality awards.

The company obtained a certificate for the voluntary Good Manufacturing Practice program for cosmetics from the Ministry of Health and Welfare.

The UK website BEST ADVISOR evaluated the best blood glucose meters in the UK. According to the announcement, Visgeneer’s eBwell was recognized for producing the most accurate readings in the evaluation.

The Commercial Times “Company Updates” section featured the article “Visgeneer prepares for its next leap, plans listing application in Q1 next year.”

Interview in the UK publication PharmaBoardroom: Ken-Shwo Dai — President and CEO, Visgeneer, Taiwan.

Visgeneer participated in Cosmoprof Asia 2016, presenting its newly developed, high-quality CORESENCE skincare products to an international audience and receiving recognition and praise from attendees.

The Commercial Times, page A22, “Industry Focus,” featured the article “Visgeneer: strong momentum in innovation.”

The Commercial Times, page C5, “Finance and Wealth Management,” featured the article “Visgeneer: a rising star.”

Visgeneer participated in the 2015 beauty exhibition in Italy, presenting its newly developed, high-quality CORESENCE skincare products to an international audience and receiving recognition and praise from attendees.

The Commercial Times, page C8, “Industry Focus,” featured the article “Visgeneer steps up progress on products and production capacity.”

Visgeneer announced its participation in the 2015 beauty exhibition in Italy, scheduled for March 20–23, 2015, and welcomed visitors from all sectors.

The Economic Daily News, page A19, “Business Activities,” featured the article “Visgeneer’s new factory holds topping-out ceremony, completion expected in Q2.”

The Commercial Times featured the article “Visgeneer’s new factory holds topping-out ceremony, completion expected in Q2.”

Visgeneer announced its participation in MEDICA 2014 in Düsseldorf, Germany, scheduled for November 12–15, 2014, and welcomed visitors from all sectors.

Visgeneer announced its participation in Cosmoprof Asia 2014, scheduled for November 12–14, 2014, and welcomed visitors from all sectors.

The Commercial Times published a report about the company titled “Visgeneer purchases land for major capacity expansion; new factory breaks ground on July 19.”

The Economic Daily News, page C1, “Securities and Industry,” published a report about the company titled “Visgeneer’s new factory groundbreaking draws distinguished guests.”

A city government news report covered the company’s new factory groundbreaking ceremony, noting that Mayor Hsu Ming-tsai attended by invitation on July 19.

The Commercial Times published a report about the company titled “Blood glucose meter specialist Visgeneer further expands into health foods.”

The Commercial Times “Stocks and Securities” section published a report about the company titled “Strong orders drive Visgeneer to buy land for major capacity expansion.”

The Commercial Times “Stock Market Highlights” section published a report about the company titled “Visgeneer meets stock dividend targets for two consecutive years.”

The Commercial Times “Healthy Living” section published a report about the company titled “Visgeneer posts strong performance, plans OTC listing application this year.”

The Commercial Times “Health and Wellness” section published a report about the company titled “Visgeneer develops remote care to drive sales.”

The Commercial Times “Stock Market Vanguard” section published a report about the company titled “Diversified earnings brighten Visgeneer’s operating outlook.”

China Times online published a Commercial Times industry supplement report about the company titled “Visgeneer enters the health and wellness market.”

China Times online published a Commercial Times industry supplement report about the company titled “Visgeneer specializes in blood glucose meters.”

The company’s shares began trading on the Emerging Stock Board.

The company’s cosmetics factory obtained ISO 22716:2007 certification.

The Economic Daily News “Medical and Senior Care” supplement published a report about the company titled “Visgeneer’s blood glucose meters and test strips achieve 50% annual growth.”

Issue 334 of the biweekly Trade Insight featured the article “Ken-Shwo Dai leads Visgeneer toward a promising future in biotechnology.”

From this date, Beijing Kangda Bainian Biotechnology Co., Ltd. became the company’s sole general distributor for blood glucose meters and test strips in mainland China, with full responsibility for sales, after-sales service and logistics distribution.

The Economic Daily News “Industry Opportunities” section published a report on the company’s zeaxanthin development titled “Visgeneer’s zeaxanthin opens doors to the US market.”

Vigenent Biotechnology Co., Ltd., the company’s wholly owned subsidiary, received an approval letter from the Industrial Development Bureau, Ministry of Economic Affairs, confirming eligibility as an emerging important strategic industry. (Reference: 工證化字第0990143010號)

The company received an approval letter from the Industrial Development Bureau, Ministry of Economic Affairs, confirming eligibility as an emerging important strategic industry. (Reference: 工證化字第09801039840號)

The application by Vigenent Biotechnology Co., Ltd., the company’s wholly owned subsidiary, for an investment project in the Biomedical Park of Hsinchu Science Park was approved at the 103rd meeting of the Science Park Review Committee of the National Science Council, Executive Yuan.

The company’s general manager, Ken-Shwo Dai, was interviewed by the Industrial Technology Research Institute. The interview appeared in the February 2010 issue of Industrial Technology and Information Monthly under the title “Making blood glucose meters ‘bigger’ and ‘smaller’: Visgeneer charts its own path.”

The company’s general manager, Ken-Shwo Dai, was interviewed by the Economic Daily News. The interview appeared in its “Business Intelligence” section under the title “Technological advantages open up the biotechnology market.”

The company received an award for outstanding innovation and R&D at an ICT industry advisory program results presentation organized by the Department of Industrial Technology, Ministry of Economic Affairs. Chairman Ken-Shwo Dai was also invited to share the company’s success story at the event.

An extraordinary shareholders’ meeting approved a spin-off to establish a new, wholly owned subsidiary.

The company’s general manager, Ken-Shwo Dai, was interviewed by the Economic Daily News. The interview appeared in its industry and technology supplement under the title “With cost advantages, Visgeneer develops a bacterial strain for macular pigment and enters the biotechnology market.”

The company was awarded a 2009 Small Business Innovation Research (SBIR) project by the Department of Industrial Technology, Ministry of Economic Affairs. Project title: “Development of applications and functions of macular pigment from Olleya marilimosa and investigation of optimal mass-production conditions.”

The company’s medical devices — blood glucose meters and blood glucose test strips — won an Indian government tender.

On August 24, 2009, Wei-Gong Memorial Hospital’s Institutional Review Board approved a collaborative research project with the company. The project was titled “Analysis of the correlation between blood glucose concentration and uric acid concentration in patients with diabetes.”

The company obtained a completion certificate for an emerging important strategic industry from the Ministry of Economic Affairs. (Reference: 工中字第09805024190號)

The company obtained utility model patent certificate No. 1214002 from the State Intellectual Property Office of the People’s Republic of China. Title: “Portable rechargeable voice biosensor.”

The company’s CoreSence skincare range passed Chunghwa Post Co., Ltd.’s review and was approved for sale through post office channels.

To meet business and production needs, the company purchased factory and office premises on Gongdao 5th Road in Hsinchu City.

The Industrial Development Bureau, Ministry of Economic Affairs, approved the addition of product categories to the company’s emerging important strategic industry investment plan originally approved on January 23, 2008, under reference 工證化字第09600967610號. (Approval reference: 工化字第09700612140號)

The company participated in the 2008 AACC medical device exhibition in the United States from July 28 to August 1, 2008. Its blood glucose meters and three-in-one multifunction home testing devices received a positive response.

The company’s annual shareholders’ meeting elected directors and supervisors. Taiwan Fertilizer Co., Ltd. secured one director seat and one supervisor seat.

The Economic Daily News published the report “Visgeneer expects to turn profitable this year.”

The company’s blood glucose analyzer obtained medical device product registration from the State Food and Drug Administration of the People’s Republic of China.

The company received an approval letter from the Industrial Development Bureau, Ministry of Economic Affairs, confirming eligibility as an emerging important strategic industry. (Reference: 工證化字第09600967610號)

An extraordinary shareholders’ meeting elected Taiwan Fertilizer Co., Ltd. to an additional seat on the company’s board of directors.

The company participated in the MEDICA 2007 medical equipment exhibition in Düsseldorf, Germany, from November 14 to 17, 2007.

The company obtained a completion certificate for an emerging important strategic industry from the Ministry of Economic Affairs. (Reference: 工中字第09605022930)

The company’s blood glucose meter factory passed Taiwan’s medical device Good Manufacturing Practice inspection. (GMP registration No. 0960302217)

Following approval by the Institutional Review Board of the Department of Health’s Hsinchu Hospital on February 8, 2007, the company signed a collaborative research agreement on February 27, 2007.

The company’s eBsensor blood glucose meter kit obtained authorization for sale as a medical device in the European Union. (CE0123)

The company’s medical device factory obtained ISO 13485:2003 certification.

The eBsensor blood glucose meter kit obtained medical device marketing clearance from the US Food and Drug Administration. (510(k) No. K062555)

The company’s cosmetics factory obtained ISO 9001:2000 certification from TUV PS.

The company received a 2006 Small Business Innovation Research (SBIR) grant from the Department of Industrial Technology, Ministry of Economic Affairs, under the program encouraging SMEs to develop new technologies. Project title: “Research into the mechanisms of carcinogenesis in T-lymphoblastic lymphoma.”

The blood glucose meter achieved compliance with EN 61010-1 (2001).

The blood glucose meter achieved compliance with EN 61326-1.

The company received an approval letter from the Industrial Development Bureau, Ministry of Economic Affairs, confirming eligibility as an emerging important strategic industry. (Reference: 工證化字第09500828690號)

A clinical study of the eBsensor blood glucose meter was published in Clin Chim Acta under the title “Clinical evaluation of the eBsensor hand-held blood glucose monitoring system.”

The blood glucose meter achieved compliance with EN 60601-1 (1990) + A1 (1993) + A2 (1995) + A13 (1996).

The blood glucose meter achieved compliance with EN 60601-1-2:2000.